Research programme: cancer therapeutics - sanofi-aventis
Alternative Names: SAR 131675; SAR132885; SAR412988; SAR567530; SSR250411Latest Information Update: 04 Nov 2017
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Centromere protein E inhibitors; HSP90 heat-shock protein inhibitors; Vascular endothelial growth factor receptor-3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
- 16 Nov 2011 Pharmacodynamics data from a Preclinical trial in Cancer presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)
- 08 Jun 2010 Pharmacodynamics and adverse events data from a preclinical trial in Cancer presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)